Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension

NCT02487407 is registered in ClinicalTrials.gov with Orion Corporation, Orion Pharma as lead sponsor.

NCT NCT02487407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02487407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension
Lead sponsor
Orion Corporation, Orion Pharma
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2015
Completion date
June 30, 2017
Enrollment
66 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis